Helicobacter pylori eradication in Parkinson disease: A randomized placebo‐controlled trial
Movement Disorders Oct 01, 2020
Tan AH, Lim SY, Mahadeva S, et al. - This study was undertaken to investigate if eradication of Helicobacter pylori (HP) has any impact on Parkinson's disease (PD) symptoms. Researchers conducted a parallel‐group, double‐blind, randomized placebo‐controlled, single‐center trial where they randomized patients with PD with positive HP urea breath test and serology in a 1:1 ratio to receive standard eradication triple therapy or identically appearing placebo capsules for 1 week. Researchers screened 310 patients for eligibility, 80 were randomly assigned, of whom 67 were included in the full analysis (32 treatment group patients, 35 placebo patients). MDS‐UPDRS motor scores at week 12 did not improve after HP eradication. At weeks 12 and 52, no significant improvement in any motor, nonmotor, or quality‐of‐life outcome was seen. Clinical outcomes in PD were not improved by HR eradication, implying that there is no justification for routine HP screening or eradication with the goal of improving PD symptoms.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries